Abstract
Anorexia nervosa is a syndrome, that is collections of symptoms, which is not defined by its etiology. The severe cases are intractable. The syndrome is associated with multiple, profound endocrine alterations which may be adaptive, reactive or etiologic. Adaptive changes potentially may be inappropriate in clinical settings such as inpatient intensive re-nutrition or in a setting with somatic comorbidity. Electrolyte levels must be closely monitored during the refeeding process, and the need for weight gain must be balanced against potentially fatal refeeding complications. An important focus of clinical research should be to identify biomarkers associated with different stages of weight loss and re-nutrition combined with psychometric data. Besides well-established peripheral endocrine actions, several hormones also are released directly to different brain areas, where they may exert behavioral and psychogenic actions that could offer therapeutic targets. We need reliable biomarkers for predicting outcome and to ensure safe re-nutrition, however, first of all we need them to explore the metabolism in anorexia nervosa to open new avenues with therapeutic targets. A breakthrough in our understanding and treatment of this whimsical disease remains. Considering this, the aim of the present review is to provide an updated overview of the many endocrine changes in a clinical perspective.
Invited Author’s profile
Rene Klinkby Støving, MD, PhD, is an endocrinologist and professor in eating disorders, University of Southern Denmark, and Mental Health Services in the Region of Southern Denmark. He hasextensive clinical experience in anorexia nervosa having contributed to the establishment of an interdisciplinary center at Odense University Hospital in 1993. In 2010, he established the only specialized endocrine unit in Denmark for patients with severe anorexia nervosa. His research areas are clinical endocrinology and epidemiological studies of anorexia nervosa.
Introduction
Anorexia nervosa (AN) is a syndrome as it describes a collection of symptoms and is not defined by an etiology. It is characterized by disturbed body image, ego-syntonic neglect, ambivalence, self-starvation, loss of body weight, obsessive thoughts of food, ritualistic patterns of food intake, elevated physical activity, depression, anxiety and emotional rigidity. The severity varies from mild subclinical cases to chronic enduring and fatal cases. The diagnostic criteria were revised in 2013 for the Fifth Edition of the Diagnostic and Statistical Manual (1), leading to markedly increased diagnostic heterogeneity and a 30–50% increase in lifetime prevalence (2, 3), which is estimated to be 1–4% (4). Diagnostic boundaries, which are based on symptoms, may not reflect the underlying pathophysiological mechanisms. The evidence base for treatment is still very limited (5). There was no evidence that the prognosis has improved throughout the 20th century (6). However, since that the outcome may have improved with an evolutionary neuroscience approach to treatment (7).
AN is associated with multiple, profound endocrine disturbances (8, 9, 10), and adaptation to chronic semi-starvation allows survival even with extreme emaciation (11). The endocrine alterations can be adaptive, reactive or etiologic. For instance, hypothalamic amenorrhea is often secondary, but it can precede the weight loss and persist for a long time after weight and motor activity have returned to normal (12). Hypersecretion of corticotropin-releasing hormone (CRH) is a response to starvation. But at the same time, it may maintain and intensify the anorexia, physical hyperactivity and amenorrhea, thus potentially creating a vicious circle, although the latter remains to be proven. Twin studies uniquely have supported a genetic origin for the observed familial accretion in AN. Hypothetically, the same genetic factors that influence normal variation in BMI may also influence dysregulation of appetite and weight-related features in AN. This hypothesis was supported by a recent genome-wide association study which reveled genetic correlations with metabolic traits in terms of regulation of insulin, glucose and lipid (13).
The purpose of the review is to provide an updated overview of the many endocrine changes with focus on the clinical consequences. For more in-depth discussion the article refers to a number of literature reviews each of which deals with specific hormone systems in AN. It is a narrative review that is combined with my own experiences from over 25 years of clinical work with AN. The review does not consider other eating disorders than AN, and it predominantly focuses on severe illness. As several comprehensive reviews on bone metabolism in AN have been published in recent years (14, 15, 16, 17, 18), this aspect is omitted from the present review.
The refeeding syndrome
Adaptation
Natural selection has led to the evolution of hormonal systems that facilitate appropriate short-term and long-term equilibrium between energy expenditure and food intake during episodes of starvation.
Chronic and severe AN is endocrinologically characterized by an extreme adaptive mechanism that allows the patients to survive. The overall endocrinology of chronic starvation is well described (19) and is characterized by increased secretion of cortisol and growth hormone (GH) and suppressed levels of leptin, sex hormones and T3. In AN, a BMI as low as 7.8, corresponding to 65% below expected body weight, has been survived without severe sequelae (11). Since the publication of that case report, the same patient relapsed with a weight drop to BMI 7.2, which she also survived (unpublished data). This degree of emaciation far exceeds what has ever been reported in hunger strikes and hunger disasters. However, the adaptation represents a considerable risk during early re-nutrition, termed the refeeding syndrome (RFS). Refeeding in AN with serious or fatal complications is anecdotally recognized (20, 21, 22, 23, 24, 25). RFS is defined as electrolyte disturbances, principally low serum concentrations of intracellular ions such as phosphate, magnesium and potassium (26, 27). The electrolyte movements from the extracellular to the intracellular space is believed to be caused by insulin spikes (28). Thiamine (vitamin B1) deficiency is also associated with RFS (29) and manifests as Wernicke’s encephalopathy syndrome and lactic acidosis. The clinical manifestations of RFS and hypophosphatemia are cardiac failure or arrest, hemolytic anemia, delirium, seizures, coma and sudden death (27, 30). To avoid RFS, a very low initial energy level is prescribed. An unintended consequence of this approach, however, is additional weight loss or the underfeeding syndrome (http://www.rcpsych.ac.uk/files/pdfversion/CR162.pdf.). It is currently debated whether further initial restriction in carbohydrates (to prevent insulin peaks) may allow a higher energy intake early on (31). A systematic review illustrated that 26 out of 27 refeeding studies were observational and limited by bias by indication, leading the authors to conclude that there is presently no evidence to require changes to the current guidelines (32).
Clinical consequences
In severe AN, electrolyte levels must be closely monitored during the refeeding process, and the need for weight gain must be balanced against the potentially fatal complications, i.e. ‘Start low and advance slow’ (http://www.rcpsych.ac.uk/files/pdfversion/CR162.pdf, MARSIPAN. Accessed April 15, 2015). However, an overestimation of the risk may have significant clinical negative consequences. Maybe the definition of a ‘high risk’ patient is too conservative. If there is no active purging or somatic comorbidity, the arbitrary definition for high risk in adults maybe should be adjusted to below BMI 12–13. Controlled randomized studies are required.
Glucose metabolism
Adaptation
Insulin-induced hypoglycemia was used therapeutically in AN until the 1960s and represents one of the bizarre inventions in medical history (33, 34). In general, fasting levels of glucose are generally lower in AN than in controls (35, 36). Sudden unexpected death is still well described among young women with AN, and manifest hypoglycemia was recognized as the cause of death in some of these fatal cases (37). Hypoglycemic coma in AN can be refractory or repetitive, so that continuous glucose administration is required to maintain euglycemia (38, 39, 40, 41, 42). The incidence of asymptomatic or subclinical hypoglycemia is unknown. Hypoglycemia may be related to liver injury, which is well described in AN, due to protein catabolism, dehydration, anemia, hypotension, ischemia and autophagy (43, 44). Marked glycogen depletion is a frequent finding in liver biopsies (45), and the severity of liver damage predicts low glycogen storage and thus increased risk of hypoglycemia (46). Furthermore, liver enzymes may rise during the early phase of re-nutrition (47). Psychopharmacologic treatment with olanzapine has been associated with fatal hypoglycemia in AN (48).
The secretion of GH (see below) and cortisol (see below) are elevated in AN, and both are known to induce insulin resistance and thus counteract the tendency for hypoglycemia. Studies of insulin sensitivity in AN have provided contradictory results, from unchanged (49) to increased (50, 51, 52) or decreased (53). These conflicting results are related to the different techniques used to evaluate insulin sensitivity and to different disease stages not only in terms of actual BMI, but also the short-term nutritional status. Using a hyperinsulinemic–euglycemic clamp, it was observed that refeeding was associated with onset of insulin resistance (54).
Temporary stress diabetes has only been reported as individual cases (55). It is observed occasionally in my specialized unit, but to my knowledge there are no published reports of how often and under what circumstances stress diabetes occurs in hospitalized patients with AN. Gastrointestinal hormones such as glucagon-like peptide-1 (GLP-1) and amylin are released in response to a meal and probably limit the size of an ongoing meal. GLP-1 is secreted from the L cells in the mucosa of the distal intestinal tract and stimulates secretion of insulin. Amylin is co-secreted with insulin from pancreatic beta cells. The plasma levels of GLP-1 (56, 57, 58) and amylin (35, 53, 59) are both found to be low in AN, which seems to be appropriate in relation to adaptation.
Clinical consequences
The frequency of hypoglycemia and its relation to weight loss, refeeding syndrome, diagnostic subtype or other clinical characteristics has not been fully studied. Blood glucose should be monitored regularly in severe AN, especially during the night or in relation to exercise. In some centers, hypoglycemia is prevented by supplementary intravenous 10% glucose (20–40 mL/h) in the first days of refeeding (60); however, as discussed earlier, this may increase the risk of refeeding syndrome. Therefore, prophylactic 5% dextrose is used in other centers (61).
Hypothalamic–pituitary–adrenal axis (HPA axis)
Adaptation
Adrenocorticotropic hormone (ACTH) is increased together with high levels of cortisol, indicating a state of CRH hypersecretion. This is further supported by normal cortisol response to stimulation with ACTH (62, 63) but a weakened response to stimulation with CRH (64, 65). Finally, CRH hypersecretion is confirmed by measurements in cerebrospinal fluid from patients with AN (64, 66). This has been evident since the 1980s. As ACTH and opioids are derived from the same prohormone (proopiomelanocortin, POMC), ACTH secretion is preceded by activation of the POMC system. The opioid system may influence hedonic eating behavior (67) and may also stimulate the urge to exercise (68). Both physical stress and psychological stress activate the HPA axis with secondary anorectic effect. In healthy individuals, a high glucocorticoid level may induce anxiety as an appropriate coping response in acute stressful events. In AN, CRH hypersecretion may be a compensatory mechanism for a state of cortisol resistance. Many animal studies show that central microinjections of CRH can lead to anorexia and increased motor activity (69) that can be reversed by CRH antagonists (70). Somatostatin counteracts the anorectic action of CRH on food intake (71), and there is evidence that the somatostatinergic tonus is impaired in AN (72), suggesting that low hypothalamic somatostatinergic activity could also be pathogenic. In weight-recovered patients, the dexamethasone suppression test predicted a continuing stress condition and high risk of relapse (73).
The hippocampus belongs to the limbic system and is a critical structure for memory functions. It contains many glucocorticoid receptors and thus may be vulnerable to long-term stress. In fact, neuroimaging studies have clearly shown that hippocampal atrophy is related to chronic stress and hypercortisolemia in studies on Cushing's syndrome (74), depression (75, 76) and AN (77).
Neurosteroids are steroids that are synthesized de novo in the brain. They are supposed to exert a negative feedback on the HPA axis and to be implicated in anxiety disorders (78). Neurosteroids may have important therapeutic potential (78), but this remains to be clarified. So far, studies on neurosteroids in AN have been conducted on circulatory levels only (79) and cannot reveal true cerebral effects.
Cortisol stimulates gluconeogenesis, and cortisol levels in AN are shown to be inversely correlated to fasting glucose (80). This suggests that increased cortisol secretion (like increased GH secretion) in AN is an adaptive mechanism to maintain euglycemia (see section above).
Clinical consequences
CRH may be involved in a potential vicious circle in AN (8). However, so far, the cause–effect relationship remains unclear and needs to be resolved by further experimental analysis. Thus, the therapeutic potential of cortisol suppressants should be further explored. This was explicitly discussed in a recent review (81). There is preliminary evidence that anti-glucocorticoid therapies could be useful in the treatment of major depression (82, 83, 84), and the degree of cortisol elevation was related to depression and anxiety measures in 18 patients with AN (85). Mifepristone is a potent progesterone primarily used for medical abortion (86). In addition, it is a competitive glucocorticoid antagonist that is used therapeutically in Cushing’s syndrome (87). The effect of mifepristone in AN has only been explored in a short-term study of eight patients, which found that mifepristone increased urinary free cortisol excretion and early morning cortisol plasma levels (88). To my knowledge, the effects of cortisol synthesis inhibitors, like ketoconazole and metyrapone, have not been explored in AN.
Hypothalamic–pituitary–thyroid axis
Adaptation
Low levels of thyroid hormone decrease resting energy expenditure (REE) (89). Self-starvation and weight loss is followed by adaptive decline in circulating concentrations of T3, T4 and thyroid-binding globulin (TBG) to downgrade the metabolic rate and REE (90, 91) (Low T3 Syndrome). Reverse T3 is elevated from increased peripheral deiodination of T4 (92, 93, 94). The TSH level is normal or slightly decreased, while the TSH response to exogenous TRH stimulation is blunted and delayed (95). During weight recovery, total T3 rises with the rising metabolic rate (96). In AN the thyroid gland is atrophic even at normal TSH levels (97).
Clinical consequences
It may be useful to monitor T3 levels during a treatment course to assess metabolic adaptation and recovery goal weights.
A relationship between AN and depressive symptoms is well established. Moreover, there is higher prevalence of primary affective disorders in the relatives of AN patients, and evidence for common genetic factors has been provided (98). Thyroid disorders are associated with affective disturbances, which may persist even after appropriate substitution (99). Exogenous administration of thyroxine, TSH or TRH was found to exert an antidepressant effect or to amplify the antidepressant effect of imipramine in primary affective disorders (100, 101). However, evidence is lacking for causal relationships and yet there is no evidence to support a beneficial therapeutic effect of thyroid hormones in AN. On the contrary, it would probably increase the cardiovascular risk by eliminating the adaptive bradycardia and low REE. Finally, there is a problematic abuse potential of thyroxine treatment in AN. This may be overlooked, as it is not addressed in the literature except for a single case report (102).
Hypothalamic–pituitary–gonadal axis
Adaptation
From an evolutionary perspective, it is fitting that the reproductive system shuts down in times of hunger and stress. In adult women with AN, earlier studies have shown immature, prepubertal, low-amplitude LH pulses that reverse with weight gain (103). The altered LH pulsatility manifests as hypothalamic amenorrhea. The immature LH secretion pattern can also be induced in experimental starvation of healthy subjects (104). The gonadotropin secretion is stimulated by estradiol (105) and leptin (106), which are both decreased in AN. In addition, increased ghrelin and cortisol levels both suppress gonadotropin secretion during starvation in ED (107, 108).
The pronounced skewed gender distribution in AN gives rise to considerations of sex-dependent susceptibility and potential pathogenic roles of the sex hormones. Estradiol modulates central processes of both satiating and orexigenic peptides (109). Neuroendocrine sex differences in regulation of eating behavior have been thoroughly reviewed (110, 111). Recently discovered hypothalamic peptides kisspeptin, gonadatropin-inhibitory peptide and amide-related peptide-3 all seem to be involved in the genesis of stress-induced hypothalamic amenorrhea (112), but their potential role in AN remains uncertain.
Clinical consequences
In the DSM-5 criteria, amenorrhea is no longer required for the diagnosis of AN (1) although menstrual resumption remains a clinical hallmark of recovery (https://www-nice-org-uk.proxy1-bib.sdu.dk/guidance/ng69. Eating disorders: recognition and treatment. National Health Institute for Care Excellence (NICE) 2017). Secondary amenorrhea may have many causes, including underweight. Menstrual resumption typically fails in weight recovered AN patients due to anxiety or excessive exercise. For example, in a study of 100 adolescent girls with AN, amenorrhea persisted in 15% of the women despite recovery of normal body weight (113). In a 1-year follow-up study of 57 patients who had reached a BMI of at least 18.5, only 35% had resumed menstruation (114). This is in line with a study of 113 adult women who did not use oral contraceptives and had a history of AN (12). The predicted probability of resuming menses at various BMI levels and body fat percentages was calculated, and at a BMI of 19 or a body fat percentage of 23, only 50% of the subjects were expected to resume their menstrual function (12). Furthermore, body composition measured by dual energy X-ray absorptiometry was not superior to BMI in predicting menstrual recovery in AN (12). In a small minority of patients, menstruation may recover at a quite low BMI; in a few cases, even lower than BMI 14 (12).
In athletic women with slight underweight and hypothalamic amenorrhea, administration of exogenous leptin increased pulsatile LH, resulting in an enlargement of the ovaries, increased number and sizes of dominant follicles and elevated plasma estradiol levels (115). Three of eight subjects achieved ovulatory menstrual cycles with this leptin therapy (115). In AN, however, increased leptin did not uniquely predict menstrual resumption (116), and as exogenous leptin also reduces fat mass and appetite, this is not an option in treatment of AN.
Both estrogen and testosterone play important and well-known roles in maintaining muscle, mucous membranes and bone mass. Some of these consequences of starvation-related atrophy could theoretically be alleviated by substitution with estradiol. However, several systematic reviews examining the effect of oral estrogen preparations on bone health in women with AN consistently found insufficient evidence to support this (14, 117). The lack of favorable effects could be associated with estrogen’s suppressive effect on hepatic synthesis of IGF-1, although transdermal estrogen did not suppress IGF-1 (118). In line with this, an 18-month RCT showed that transdermal physiological estrogen replacement with cyclic progesterone increased bone accrual rates in adolescents with AN (119).
Anxiety and depression are well-known features of AN, and it is possible that deficiency in sex hormones worsens these symptoms in AN. For instance, hypoandrogenemia has been associated with more severe depression and anxiety in women with AN independent of body weight (120). In adolescent girls with AN, transdermal estradiol improved the tendency to experience anxiety independently of weight changes, but it did not affect attitudes toward eating, eating behavior or body shape perception (121).
Unplanned pregnancies appear to be relatively common in AN (122, 123). Reports of increased risk for miscarriages, cesarean deliveries, premature births and perinatal lethality in women with a history of AN indicate the need for careful monitoring of these women during pregnancy and of their children (114, 124).
Growth hormone (GH) axis
Adaptation
The metabolic effects of GH are related to its pulsatile secretory pattern, and AN is a state of acquired GH resistance. Secretory burst frequency, burst mass and burst duration are increased in AN, with markedly higher daily pulsatile GH secretion and basal (non-pulsatile) GH secretion (125). Furthermore, women with AN had significantly higher GH approximate entropy scores than controls, denoting marked irregularity of the GH release process (125). The alterations in GH secretion appear to be correlated with the weight loss in AN and are reversed by refeeding (125, 126). GH pulsatility is affected by sleep and vice versa (127). Insomnia is a recognized symptom in AN and should also be considered in the treatment. Circulating levels of total ultra-filtrated (128) and bioactive (50) IGF-1 levels are greatly decreased in AN. As GH is a potent stimulator of gluconeogenesis, a beneficial effect of the higher GH and lower IGF-1 levels is maintenance of euglycemia (see above). The state of GH resistance in AN is thus adaptive through its gluconeogenic role (through increased lipolysis) to maintain euglycemia in a state of low energy availability (129). Fasting stimulates the secretion of fibroblast growth factor 21 (FGF21) from hepatocytes, adipocytes and myocytes, and FGF21 inhibits transcription 5 which is a mediator of intracellular GH effects (130). Expectedly in AN, the level of FGF21 is increased and is inversely correlated with the level of IGF-1 (131).
Placental-associated protein protein-A (PAPP-A) is abundant in the circulation of pregnant women and is widely expressed in multiple tissues. By cleaving a subset of IGF-binding proteins, PAPP-A functions as a growth-promoting enzyme within the tissues near the IGF receptor and releases bioactive IGF (132). To my knowledge, however, PAPP-A has not yet been studied in AN.
Clinical consequences
The therapeutic effects of GH in AN has only been scantily investigated. Ten girls with early-onset AN and subsequent growth failure and delayed puberty were treated with rhGH for 2 years (133). Increase in height was observed, but as there was no control group, it is not possible to separate the potential effect of rhGH from that of the nutritional interventions (133). Intranasal GH-releasing peptide-2 was administrated to one patient with severe and enduring AN who then increased body weight from 21 to 28 kg over 14 months (134). In an RCT ten patients with BMI 17.4 ± 0.4 self-administered GH for 12 weeks (135); however, supraphysiologic doses greater than five times the dose used to treat GH-deficient patients did not increase the level of IFG-1 (135). Importantly, the treatment led to a further decrease in fat mass, which can hardly be of therapeutic benefit in cachexia. Furthermore, the safety of GH treatment in hypercatabolic GH-resistant patients has been severely questioned by a multicenter trial in critically ill patients in intensive care units (136).
Ghrelin
Adaptation
Approximately 70% of circulating ghrelin is secreted by gastric cells. Ghrelin cross the blood–brain barrier and exerts multiple physiological effects that go far beyond its initial characterization as a GH secretagogue. Its strongest effect is stimulation of food intake via activation of orexigenic pathways produced by the two neuropeptides, agouti-related protein (AgRP) and neuropeptide Y (NPY). These pathways are essential for normal feeding behavior, as evidenced by the rapid arrest of feeding when these neurons are ablated in mice (137). Circulating ghrelin is present in acylated and desacylated forms, and only acylated ghrelin stimulates appetite (138). Oacyltransferase (GOAT) is the only known enzyme capable of acylating ghrelin in vivo, as indicated by the absence of acyl ghrelin in mice lacking GOAT (139). Desacyl ghrelin may act as a separate hormone through an unknown receptor (140). The broad pharmacological potential of ghrelin pathways was recently prominently reviewed (141, 142, 143).
Numerous studies have shown that the circulating level of ghrelin is elevated in AN and the plasma concentration decreases with weight gain (50, 144, 145, 146). Moreover, the secretory pulse amplitude is increased (147, 148). Obestatin is cleaved from acylated ghrelin, and the plasma level of obestatin is also increased in AN (149). Some studies have reported differences in ghrelin levels in restrictive and binge-purge subtypes of AN (150), and short-term weight gain led to an increased ratio of acylated/desacylated ghrelin. So far, genetic association studies have failed to reveal any polymorphism in ghrelin secretion as a potential etiologic factor in AN (151, 152).
To my knowledge, only one experimental intervention study has been published. In a pilot study of five patients with restrictive severe AN (BMI 10.2–14.6), supraphysiologic doses of ghrelin (3 μg/kg) were infused twice a day preprandially for 2 weeks (153). During this intervention, hunger measured by a visual analog scale increased in four of the five patients, whereas body weight decreased in three of the five patients (153). Appetite measurement by visual analog scale has not been validated in AN, and due to lack of a randomized, placebo-controlled group and blinding of the investigators, conclusions from that study cannot be drawn but should inspire subsequent studies. In another study of 30 patients with severe AN, medium-chain triglyceride (MCT) supplementation increased the level of acylated (active) ghrelin levels in a dose-dependent manner (154). However, the increase in body weight did not differ significantly between low, moderate and high MCT supplementation (154).
Clinical consequences
Increased ghrelin secretion seems an appropriate adaptive appetite-stimulating response to chronic starvation.
In theory, ghrelin agonism offers an approach in treatment of loss of appetite. Small RCTs in cachexia related to cancer and chronic obstructive pulmonary disease show promising results (155, 156, 157). Gastroparesis, nausea and other forms of gastrointestinal discomfort is very common in AN (158). An RCT with the ghrelin receptor agonist, ulimorelin, demonstrated symptomatic improvements over placebo in 23 hospitalized patients with diabetic gastroparesis (159). The ghrelin agonist, relamorelin, was recently tested in an RCT of 22 chronic, stable patients with AN (BMI 17.7 ± 0:4) (160), where 3 out of 10 patients dropped out due to an increased hunger sensation. Gastric emptying was shortened by the ghrelin agonist; however, there was no significant weight gain during 4 weeks of treatment (160). Despite this, there is obviously basis for further exploration of the therapeutic potential of ghrelin agonism in AN.
The endocannabinoid system
Adaptation
A search for ‘medical cannabis’ gives today more than 6 million hits in Google and demonstrates a huge public interest and debate. Old studies of tetrahydrocannabinol (THC) intake in humans described short-term effects in terms of elevated hunger ratings and increased food intake (161, 162). However, in cancer (163) and AIDS-related (164) cachexia, clinical trials have shown only minor weight gains.
The endogenous cannabinoid system has been characterized in detail. The system has a role in feeding-related neural and hormonal circuitry at several levels, both central and peripheral, being related to integrative functions (hypothalamus and hindbrain), hedonic evaluation of foods (limbic system), gut signaling (intestinal system and pancreas) and adipogenesis (liver and fat tissue). It was recently shown that in eating disorders, the availability of the cannabinol receptor 1 was negatively correlated with BMI throughout the mesolimbic reward system (midbrain, striatum, insula, amygdala and orbitofrontal cortex), which constitutes a pathway implicated in processing appetitive motivation and hedonic food rewards (165). The hedonic roles are of special interest in AN (166) in view of the consensus that patients with AN suffer from universal anhedonia (167) and interoceptive impairment.
Patients with AN have high peripheral concentrations of the endocannabinoids anandamide, 2-arachidonoylglycerol, oleoylethanolamide and palmitoylethanolamide (166, 168). Moreover, seven weight-recovered AN patients differed from healthy controls in peripheral endocannabinoid response to meals (166). So far, however, endocannabinoids have only been measured in a few small populations by a few research units. An increased level could be interpreted both as an appropriate (but insufficient) adaptation to malnutrition or as dysregulated reward processes.
Clinical consequences
The therapeutic perspectives in AN have previously been reviewed (169). In an old study, the effects of diazepam and high doses of THC were compared in a non-blinded randomized trial of 11 patients with AN (170). The weight gain in the THC group was slightly higher than that in the diazepam group, although the participants were occasionally tube-fed during the trial (170). An add-on, randomized double-blind, controlled crossover study of 24 patients with severe and enduring AN found that low-dosage dronabinol (10 mg daily) over 4 weeks had a statistically, but hardly clinically, significant weight-gaining effect (171). It should be noted, however, that the highest weight gain was observed in the last week of that trial (171), indicating that treatment should have been extended beyond the 4 weeks. During the 4-week treatment, dronabinol was associated with increased physical activity monitored by accelerometer (172). This contrasts with animal experimental studies (173) and a recent clinical case study using a higher dose of dronabinol (daily 15 mg), which alleviated the urge to be physically active (174).
The two small, preliminary clinical trials conducted so far have not confirmed a therapeutic potential for cannabinol in AN. However, they have not ruled out a beneficial effect either. Further explorative research should thus be done, especially in patients with severe and enduring AN. There may still be prospects for cannabinol in modulation of both feeding behavior and the anxiety, anhedonia and motor restlessness in AN.
Vasopressin
Adaptation
Vasopressin is also referred to as antidiuretic hormone, arginine vasopressin and argipressin. Hyponatremia is very common in AN (175) and may lead to complications such as vomiting, altered level of consciousness and seizures. Purging behavior is the dominant cause (176, 177); although the syndrome of inappropriate antidiuretic hormone secretion (SIADH) may also be implicated (178, 179, 180, 181). A study of 12 patients (BMI 15.2 ± 0.6) showed altered osmoregulation both at baseline (normal ADH levels despite lower plasma sodium and osmolality) and after water deprivation (lower urinary concentrating ability) (182). The study population was heterogenic in terms of pharmacologic treatment with antidepressant and oral contraceptives, however, which confounds pathogenic interpretation (182). Partial diabetes insipidus has also been documented in AN due to defective vasopressin secretion, with clinical symptoms of polyuria and polydipsia (181).
In addition to the established endocrine effects on osmoregulation and arteriole constriction, vasopressin is released directly into the brain where it is considered to be involved in social behavior, sexual motivation, depression and responses to stress (183). Animal experimental evidence of this is thoroughly reviewed (184). In humans, depression has been found to be associated with elevated levels of ADH in cerebrospinal fluid and enhanced pituitary sensitivity to ADH (185). However, in a prospective study of soldiers (n = 907) deployed to combat zones, the plasma level of vasopressin was not related to the development of post-traumatic stress syndrome over time (186). The potential pathogenic role of vasopressin in anxiety and depression in AN remains to be examined and has had little attention in AN research.
Clinical consequences
The cause of every case of hyponatremia must be carefully resolved, as correctional therapy will differ. It is particularly important to recognize hypotonic dehydration since fluid restriction in this situation will have serious consequences (187). Antidepressants are often prescribed in AN although the evidence is lacking (188), and SIADH resulting in hyponatremia is a frequent adverse effect.
It has been suggested that ADH and oxytocin (see section below) levels could be biomarkers for psychiatric disease; however, this could not be confirmed in a recent meta-analysis (189).
Oxytocin
Adaptation
Besides the established peripheral endocrine actions of oxytocin secreted from the posterior pituitary gland, it is well documented that oxytocin is also released from centrally projecting neurons directly to brain areas. In numerous human experimental studies, intranasal application of oxytocin has been claimed to exert psychological effects such as attachment (190), generosity and empathy (191, 192). Furthermore, oxytocin may possess anxiolytic and antidepressant effects (192) and affect eating behavior as well (193). Several thought-provoking trials were recently critically reviewed for publication bias and questionable post hoc interpretations (194). It was also questioned whether peripheral measurements of oxytocin reflect central release (194).
In patients with binge eating disorder and obesity (n = 7), an 8-week RCT with nasal oxytocin application combined with an energy-restricted diet showed no significant reduction in binge eating or body weight (195). Studies on oxytocin in AN have reported lower circulating levels (196, 197, 198) and lower concentrations in CSF that return to normal during refeeding (199). Increased postprandial serum level of oxytocin in 13 patients (BMI 17.7 ± 0.3) has been suggested to be adaptive to decrease the anxiety induced by meals (200). SNPs of the oxytocin receptor gene have been investigated in a few studies. One study reported higher methylation of the receptor gene in AN (201) and associations with the severity of eating disorder symptoms (202).
Clinical consequences
The clinical consequence of the above findings on oxytocin pathways in AN remains unknown. Animal experimental data have not yet been translated to clinical human studies.
Gut peptides
Adaptation
Besides their many local effects on gastrointestinal motility and secretion, gut peptides act directly on neurons in hypothalamic and brainstem centers of appetite control and influence both short-term and long-term energy balance. The most well-studied are cholecystokinin (CCK), peptide YY (PYY), glucagon-like peptide-1 (GLP-1), oxyntomodulin and ghrelin; however, the list of identified gut hormones is very long and still grows. Except for ghrelin, all the mentioned hormones act to increase satiety and decrease food intake. For ghrelin, see the section above. In AN, the CCK level in the CSF remains unchanged (203) whereas there are contradictory reports about basal and postprandial serum concentrations of CCK (204, 205, 206, 207, 208). PYY is believed to play a role in meal termination and satiety, partly by reducing appetite stimulation by ghrelin (209). Plasma levels of PYY in AN are paradoxically reported to be increased in some studies (144, 210), but decreased in other studies (211, 212). GLP-1 is supposed to be a brain-gut peptide that acts as a hormone and neurotransmitter, mediating processes related to glucose metabolism and satiety. Like PYY, there are contradictory reports of the level of GLP-1 in AN (57, 58, 213). Oxyntomodulin is a product of the glucagon precursor that co-activates the GLP-1 receptor. To my knowledge, it has so far only been measured in one study of AN, although a control group was not included in that study (214).
The potential pathogenic roles of gut hormones in AN have been comprehensively reviewed, and it was concluded that most of the observed circulating alterations dissolved after restoration of body weight, indicating adaptive rather than pathogenic roles (215, 216). The many contradictory results could be due to variations in the short-term nutritive status, which is in fact not considered in any of the above-mentioned studies. Besides the humeral pathways, a potentially important player in the gut-brain axis is the gut microbiota. In recent years, several small studies have been published (217, 218, 219, 220) as well as 13 reviews focusing on the microbiota specifically related to AN (221, 222, 223, 224, 225, 226). The exploration of this essential area is still in its infancy. Caseinolytic protease b (ClpB) is an example of a peptide produced in the gut bacteria, and ClpB has been identified as a mimetic of α-melanocyte-stimulating hormone, a neuropeptide which are supposed to be involved in satiety and anxiety signaling (227). Remarkably, the plasma level of ClpB has been found to be increased in patients with AN (228).
Clinical consequences
The gut peptides probably play a critical part in adaptation to starvation and refeeding, but their exact roles are not yet clarified. Speculatively, they might contribute to the maintenance of disordered eating behavior and may also influence the outcome.
Adipokines
Adaptation
Adipokines are cytokines that are secreted by adipose tissue and modulate energy expenditure, glucose homeostasis, and appetite regulation. Leptin is by far the most extensively studied. Reduced serum levels of leptin in AN (229) reflect decreased fat mass and appear to be an appropriate adaptation to reduce an anorexigenic stimulus that increases with refeeding and recovery (both free and bound leptin) (230, 231). Extensive and compulsive exercise is common in AN (232) and is not just compensatory to burn calories (233, 234). Starvation in animals has consistently been reported to induce motoric hyperactivity (235), and there is evidence that leptin deficit is implicated in this phenomenon as leptin administration prevents starvation-induced hyperactivity (236, 237). Although animal experimental data must be translated to humans with caution, from an evolutionary perspective, an increased drive for physical activity seems appropriate to facilitate finding food. This is supported by the finding that leptin levels were lower in men with exercise addiction compared to non-addictive exercisers, even when adjusted for body fat percentage (238). However, an accelerometric study of 61 hospitalized patients with AN (BMI 14.8 ± 2.0) did not reveal a clear association between leptin levels and physical activity (239).
The adaptive roles of adiponectin in AN have been thoroughly reviewed (240). Adiponectin exists in several isoforms with specific receptors (241) and has insulin-sensitizing properties. Serum levels are negatively correlated to BMI and body fat mass (242). In line with this, most studies found increased circulating levels of adiponectin in AN, which decrease during refeeding (52, 243, 244). In animal studies, intracerebroventricular administration of adiponectin has been shown to decrease body weight. In human studies, peripheral administration of adiponectin reduces body weight by enhancing energy expenditure and fatty acid oxidation and by reducing food intake (245). Based on these observations, it has been suggested that hyperadiponectinemia could contribute to the pathogenesis of AN (240, 246).
Visfatin is mainly synthesized in abdominal adipose tissue. Like the other adipokines, it is implicated in adipocyte differentiation and is metabolically active in energy and body-weight regulatory networks. In contrast to the circular levels of adiponectin and leptin in AN, the studies on visfatin in AN have so far produced conflicting results (247, 248, 249).
Clinical consequences
The therapeutic potential of leptin is briefly discussed in the section above (section Hypothalamic–pituitary–gonadal axis). In addition, severe hypoglycemia can be a serious clinical challenge, as mentioned above (section Glucose metabolism). Hypothetically, the increased level of insulin-sensitizing adiponectin may aggravate this problem (250).
Myokines
Adaptation
Myokines are produced and released by muscle cells in response to muscular contractions and, like the adipokines, they have autocrine, paracrine and endocrine effects (251, 252). The myokines are believed to represent a link between the myocyte and the beneficial mental effects of exercise. For instance, a meta-analysis of 42,264 persons indicated that exercise exerts antidepressant and anxiolytic effects (252).
Irisin, previously named fibronectin type III domain-containing protein 5, is a myokine involved in browning of white adipose tissue, making it metabolically active and capable of increasing thermogenesis. Irisin has been reported to be decreased in AN (253) and thus probably represents another adaptive mechanism to conserve energy through less browning of white fat. It is found not to be affected by exercise in patients with AN in contrast to healthy controls (254), possibly due to the muscle catabolism in these patients.
Brain-derived neurotrophic factor (BDNF) is one of the neurotrophic growth factors found in the brain, but it also belongs to the family of myokines. Intracerebral infusion of BDNF in animals enhanced physical activity and modulated thermogenesis (255). Studies on circulating levels of BDFN in AN have shown conflicting results (256, 257, 258), indicating that the serum levels are influenced by multiple factors such as nutritive status, exercise, and anxiety.
Clinical consequences
At this point, myokines have no clinical consequences in AN. Several myokines remain to be studied in AN, e.g. myostain and follistatin, and they could prove to be important in our understanding of starvation-induced excessive exercise and anxiety in AN.
Clinical Conclusions
Nearly all the endocrine systems are profoundly altered in severe AN. An important focus of clinical research in AN should be to identify biomarkers associated with different stages of both weight loss and refeeding, and then to assess their psychometric properties. Several of the many hormones mentioned above have the potential to serve as useful clinical biomarkers, however much research is still needed. Strong attention to the evolutionary perspectives and to the stage of the disease should be kept in this research. In every endocrinologically study of AN, it is not enough to include BMI in the interpretation but also the current nutritional status, e.g. expressed as short term relative weight change over the past 1–4 weeks and levels of exercise needs to be considered. Potential biomarkers should also be related to the plasma concentration of classical metabolic parameters such as T3 and insulin. Several ‘new’ peptides remain to be studied in AN, e.g. kisspeptin, gonadatropin-inhibitory peptide, and amide-related peptide-3, myostain, follistatin and PAPP-A. The important animal experimental data on oxytocin remains to be translated to human studies. We need biomarkers firstly to explore metabolism in AN to open new avenues of therapeutic targets, and secondly for predicting outcome and to ensure safe refeeding. A breakthrough in our understanding and treatment of this whimsical disease is still awaited.
Limitations
This is a narrative review based exclusively on English language articles indexed in MedLine. Original studies and reviews from the past 15 years were mainly selected, but commonly referenced older publications were not excluded. The conclusions are influenced by the authors own experiences from more than 25 years of clinical work with AN, and are not generated by meta-analyses of systematic reviews. This weakens the evidence and should be taken into consideration.
Declaration of interest
The author declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.
Funding
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.
Acknowledgements
Claire Margaret Gudex is thanked for skilled proofreading and review of the references.
References
- 1↑
American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders, edn 5. Washington: APA, 2013.
- 2↑
Mustelin L, Silen Y, Raevuori A, Hoek HW, Kaprio J & Keski-Rahkonen A. The DSM-5 diagnostic criteria for anorexia nervosa may change its population prevalence and prognostic value. Journal of Psychiatric Research 2016 77 85–91. (https://doi.org/10.1016/j.jpsychires.2016.03.003)
- 3↑
Mancuso SG, Newton JR, Bosanac P, Rossell SL, Nesci JB & Castle DJ. Classification of eating disorders: comparison of relative prevalence rates using DSM-IV and DSM-5 criteria. British Journal of Psychiatry 2015 206 519–520. (https://doi.org/10.1192/bjp.bp.113.143461)
- 4↑
Keski-Rahkonen A & Mustelin L. Epidemiology of eating disorders in Europe: prevalence, incidence, comorbidity, course, consequences, and risk factors. Current Opinion in Psychiatry 2016 29 340–345. (https://doi.org/10.1097/YCO.0000000000000278)
- 5↑
Watson HJ & Bulik CM. Update on the treatment of anorexia nervosa: review of clinical trials, practice guidelines and emerging interventions. Psychological Medicine 2013 43 2477–2500. (https://doi.org/10.1017/S0033291712002620)
- 6↑
Steinhausen H-C. The outcome of anorexia nervosa in the 20th century. American Journal of Psychiatry 2002 159 1284–1293. (https://doi.org/10.1176/appi.ajp.159.8.1284)
- 7↑
Bergh C, Callmar M, Danemar S, Holcke M, Isberg S, Leon M, Lindgren J, Lundqvist A, Niinimaa M & Olofsson B et al.Effective treatment of eating disorders: results at multiple sites. Behavioral Neuroscience 2013 127 878–889. (https://doi.org/10.1037/a0034921)
- 8↑
Stoving RK, Hangaard J, Hansen-Nord M & Hagen C. A review of endocrine changes in anorexia nervosa. Journal of Psychiatric Research 1999 33 139–152. (https://doi.org/10.1016/S0022-3956(98)00049-1)
- 9↑
Singhal V, Misra M & Klibanski A. Endocrinology of anorexia nervosa in young people: recent insights. Current Opinion in Endocrinology, Diabetes and Obesity 2014 21 64–70. (https://doi.org/10.1097/MED.0000000000000026)
- 10↑
Misra M & Klibanski A. Endocrine consequences of anorexia nervosa. Lancet Diabetes and Endocrinology 2014 2 581–592. (https://doi.org/10.1016/S2213-8587(13)70180-3)
- 11↑
Frolich J, Palm CVB & Stoving RK. To the limit of extreme malnutrition. Nutrition 2016 32 146–148. (https://doi.org/10.1016/j.nut.2015.08.024)
- 12↑
Winkler LA-D, Frolich JS, Schulpen M & Stoving RK. Body composition and menstrual status in adults with a history of anorexia nervosa-at what fat percentage is the menstrual cycle restored? International Journal of Eating Disorders 2017 50 370–377. (https://doi.org/10.1002/eat.22600)
- 13↑
Duncan L, Yilmaz Z, Gaspar H, Walters R, Goldstein J, Anttila V, Bulik-Sullivan B, Ripke S, Thornton L & Hinney A et al.Significant locus and metabolic genetic correlations revealed in genome-wide association study of anorexia nervosa. American Journal of Psychiatry 2017 174 850–858. (https://doi.org/10.1176/appi.ajp.2017.16121402)
- 14↑
Misra M & Klibanski A. Anorexia nervosa and bone. Journal of Endocrinology 2014 221 R163–R176. (https://doi.org/10.1530/JOE-14-0039)
- 15↑
Fazeli PK & Klibanski A. Bone metabolism in anorexia nervosa. Current Osteoporosis Reports 2014 12 82–89. (https://doi.org/10.1007/s11914-013-0186-8)
- 16↑
Misra M & Klibanski A. Bone health in anorexia nervosa. Current Opinion in Endocrinology, Diabetes, and Obesity 2011 18 376–382. (https://doi.org/10.1097/MED.0b013e32834b4bdc)
- 17↑
Robinson L, Micali N & Misra M. Eating disorders and bone metabolism in women. Current Opinion in Pediatrics 2017 29 488–496. (https://doi.org/10.1097/MOP.0000000000000508)
- 18↑
Fazeli PK & Klibanski A. Effects of anorexia nervosa on bone metabolism. Endocrine Reviews 2018 Epub. (https://doi.org/10.1210/er.2018-00063)
- 19↑
Stoving RK, Hangaard J & Hagen C. Update on endocrine disturbances in anorexia nervosa. Journal of Pediatric Endocrinology and Metabolism 2001 14 459–480.
- 20↑
Derman T & Szabo CP. Why do individuals with anorexia die? A case of sudden death. International Journal of Eating Disorders 2006 39 260–262. (https://doi.org/10.1002/eat.20229)
- 21↑
Sakamoto Y, Kioka H, Hashimoto R, Takeda S, Momose K, Ohtani T, Yamaguchi O, Wasa M, Nakatani S & Sakata Y. Cardiogenic shock caused by a left midventricular obstruction during refeeding in a patient with anorexia nervosa. Nutrition 2017 35 148–150. (https://doi.org/10.1016/j.nut.2016.12.017)
- 22↑
Patel AS, Matthews L & Bruce-Jones W. Central pontine myelinolysis as a complication of refeeding syndrome in a patient with anorexia nervosa. Journal of Neuropsychiatry and Clinical Neurosciences 2008 20 371–373. (https://doi.org/10.1176/jnp.2008.20.3.371)
- 23↑
Kishibe M, Sakai H & Iizuka H. Acute edema/cutaneous distention syndrome associated with refeeding in a patient with anorexia nervosa. Archives of Dermatology 2009 145 1202–1203.
- 24↑
Kohn MR, Golden NH & Shenker IR. Cardiac arrest and delirium: presentations of the refeeding syndrome in severely malnourished adolescents with anorexia nervosa. Journal of Adolescent Health 1998 22 239–243. (https://doi.org/10.1016/S1054-139X(97)00163-8)
- 25↑
De Caprio C, Alfano A, Senatore I, Zarrella L, Pasanisi F & Contaldo F. Severe acute liver damage in anorexia nervosa: two case reports. Nutrition 2006 22 572–575. (https://doi.org/10.1016/j.nut.2006.01.003)
- 26↑
Vignaud M, Constantin J-M, Ruivard M, Villemeyre-Plane M, Futier E, Bazin J-E, Annane D, Group A, Constantin SC & Guerin R et al. Refeeding syndrome influences outcome of anorexia nervosa patients in intensive care unit: an observational study. Critical Care 2010 14 R172. (https://doi.org/10.1186/cc9274)
- 27↑
Ormerod C, Farrer K, Harper L & Lal S. Refeeding syndrome: a clinical review. British Journal of Hospital Medicine 2010 71 686–690. (https://doi.org/10.12968/hmed.2010.71.12.686)
- 28↑
Ross JR & Taylor SN. Hyperinsulinemia has prominent role in refeeding syndrome pathophysiology. Journal of Perinatology 2014 34 247–248. (https://doi.org/10.1038/jp.2013.188)
- 29↑
Hershkowitz E, Reshef A, Munich O, Yosefi B & Markel A. Thiamine deficiency in self-induced refeeding syndrome, an undetected and potentially lethal condition. Case Reports in Medicine 2014 2014 605707. (https://doi.org/10.1155/2014/605707)
- 30↑
Araujo Castro M & Vazquez Martinez C. The refeeding syndrome. Importance of phosphorus. Medicina Clinica 2018 150 472–478. (https://doi.org/10.1016/j.medcli.2017.12.008)
- 31↑
Katzman DK. Refeeding hospitalized adolescents with anorexia nervosa: is “start low, advance slow” urban legend or evidence based? Journal of Adolescent Health 2012 50 1–2. (https://doi.org/10.1016/j.jadohealth.2011.10.003)
- 32↑
Garber AK, Sawyer SM, Golden NH, Guarda AS, Katzman DK, Kohn MR, Le Grange D, Madden S, Whitelaw M & Redgrave GW. A systematic review of approaches to refeeding in patients with anorexia nervosa. International Journal of Eating Disorders 2016 49 293–310. (https://doi.org/10.1002/eat.22482)
- 33↑
Wilson DC, Rymarkiewiczowa D & White WM. Anorexia nervosa with special regard to insulin therapy. Southern Medical Journal 1946 39 408–416. (https://doi.org/10.1097/00007611-194605000-00010)
- 34↑
Dally P & Sargant W. Treatment and outcome of anorexia nervosa. British Medical Journal 1966 2 793–795. (https://doi.org/10.1136/bmj.2.5517.793)
- 35↑
Misra M, Miller KK, Cord J, Prabhakaran R, Herzog DB, Goldstein M, Katzman DK & Klibanski A. Relationships between serum adipokines, insulin levels, and bone density in girls with anorexia nervosa. Journal of Clinical Endocrinology and Metabolism 2007 92 2046–2052. (https://doi.org/10.1210/jc.2006-2855)
- 36↑
Connan F, Lightman S & Treasure J. Biochemical and endocrine complications. European Eating Disorders Review 2000 8 144–157. (https://doi.org/10.1002/(SICI)1099-0968(200003)8:2<144::AID-ERV340>3.0.CO;2-B)
- 37↑
Rich LM, Caine MR, Findling JW & Shaker JL. Hypoglycemic coma in anorexia nervosa. Case report and review of the literature. Archives of Internal Medicine 1990 150 894–895. (https://doi.org/10.1001/archinte.1990.00390160134027)
- 38↑
Shimizu K, Ogura H, Wasa M, Hirose T, Shimazu T, Nagasaka H, Hirano K-i. Refractory hypoglycemia and subsequent cardiogenic shock in starvation and refeeding: report of three cases. Nutrition 2014 30 1090–1092. (https://doi.org/10.1016/j.nut.2014.01.007)
- 39↑
Gaudiani JL, Sabel AL, Mascolo M & Mehler PS. Severe anorexia nervosa: outcomes from a medical stabilization unit. International Journal of Eating Disorders 2012 45 85–92. (https://doi.org/10.1002/eat.20889)
- 40↑
de Jager CM, Hoekstra M, Nijsten MWN, Lansink AO & Ismael F. Metabolic and neurologic sequelae in a patient with long-standing anorexia nervosa who presented with septic shock and deep hypoglycemia. International Journal of Eating Disorders 2011 44 756–759. (https://doi.org/10.1002/eat.20863)
- 41↑
Yanai H, Yoshida H, Tomono Y & Tada N. Severe hypoglycemia in a patient with anorexia nervosa. Eating and Weight Disorders 2008 13 e1–e3. (https://doi.org/10.1007/BF03327785)
- 42↑
Bando N, Watanabe K, Tomotake M, Taniguchi T & Ohmori T. Central pontine myelinolysis associated with a hypoglycemic coma in anorexia nervosa. General Hospital Psychiatry 2005 27 372–374. (https://doi.org/10.1016/j.genhosppsych.2005.03.004)
- 43↑
Rosen E, Sabel AL, Brinton JT, Catanach B, Gaudiani JL & Mehler PS. Liver dysfunction in patients with severe anorexia nervosa. International Journal of Eating Disorders 2016 49 151–158. (https://doi.org/10.1002/eat.22436)
- 44↑
Rosen E, Bakshi N, Watters A, Rosen HR & Mehler PS. Hepatic complications of anorexia nervosa. Digestive Diseases and Sciences 2017 62 2977–2981. (https://doi.org/10.1007/s10620-017-4766-9)
- 45↑
Kransdorf LN, Millstine D, Smith ML & Aqel BA. Hepatic glycogen deposition in a patient with anorexia nervosa and persistently abnormal transaminase levels. Clinics and Research in Hepatology and Gastroenterology 2016 40 e15–e18. (https://doi.org/10.1016/j.clinre.2015.05.001)
- 46↑
Sakurai-Chin C, Ito N, Taguchi M, Miyakawa M, Takeshita A & Takeuchi Y. Hypoglycemic coma in a patient with anorexia nervosa coincident with acute exacerbation of liver injury induced by oral intake of nutrients. Internal Medicine 2010 49 1553–1556. (https://doi.org/10.2169/internalmedicine.49.3373)
- 47↑
Harris RH, Sasson G & Mehler PS. Elevation of liver function tests in severe anorexia nervosa. International Journal of Eating Disorders 2013 46 369–374. (https://doi.org/10.1002/eat.22073)
- 48↑
Haruta I, Asakawa A & Inui A. Olanzapine-induced hypoglycemia in anorexia nervosa. Endocrine 2014 46 672–673. (https://doi.org/10.1007/s12020-014-0235-9)
- 49↑
Castillo M, Scheen A, Lefebvre PJ & Luyckx AS. Insulin-stimulated glucose disposal is not increased in anorexia nervosa. Journal of Clinical Endocrinology and Metabolism 1985 60 311–314. (https://doi.org/10.1210/jcem-60-2-311)
- 50↑
Stoving RK, Chen J-W, Glintborg D, Brixen K, Flyvbjerg A, Horder K & Frystyk J. Bioactive insulin-like growth factor (IGF) I and IGF-binding protein-1 in anorexia nervosa. Journal of Clinical Endocrinology and Metabolism 2007 92 2323–2329. (https://doi.org/10.1210/jc.2006-1926)
- 51↑
Zuniga-Guajardo S, Garfinkel PE & Zinman B. Changes in insulin sensitivity and clearance in anorexia nervosa. Metabolism: Clinical and Experimental 1986 35 1096–1100. (https://doi.org/10.1016/0026-0495(86)90021-1)
- 52↑
Delporte ML, Brichard SM, Hermans MP, Beguin C & Lambert M. Hyperadiponectinaemia in anorexia nervosa. Clinical Endocrinology 2003 58 22–29. (https://doi.org/10.1046/j.1365-2265.2003.01702.x)
- 53↑
Pannacciulli N, Vettor R, Milan G, Granzotto M, Catucci A, Federspil G, De Giacomo P, Giorgino R & De Pergola G. Anorexia nervosa is characterized by increased adiponectin plasma levels and reduced nonoxidative glucose metabolism. Journal of Clinical Endocrinology and Metabolism 2003 88 1748–1752. (https://doi.org/10.1210/jc.2002-021215)
- 54↑
Prioletta A, Muscogiuri G, Sorice GP, Lassandro AP, Mezza T, Policola C, Salomone E, Cipolla C, Della Casa S & Pontecorvi A et al.In anorexia nervosa, even a small increase in abdominal fat is responsible for the appearance of insulin resistance. Clinical Endocrinology 2011 75 202–206. (https://doi.org/10.1111/j.1365-2265.2011.04046.x)
- 55↑
Nakashima T, Kubota T, Takasugi N, Kitagawa Y, Yoshida T, Ushikoshi H, Kawasaki M, Nishigaki K, Ogura S & Minatoguchi S. Hyperglycemia and subsequent torsades de pointes with marked QT prolongation during refeeding. Nutrition 2017 33 145–148. (https://doi.org/10.1016/j.nut.2016.05.012)
- 56↑
Tomasik PJ, Sztefko K & Malek A. GLP-1 as a satiety factor in children with eating disorders. Hormone and Metabolic Research 2002 34 77–80. (https://doi.org/10.1055/s-2002-20519)
- 57↑
Tomasik PJ, Sztefko K, Cholecystokinin Starzyk J., glucose dependent insulinotropic peptide and glucagon-like peptide 1 secretion in children with anorexia nervosa and simple obesity. Journal of Pediatric Endocrinology and Metabolism 2004 17 1623–1631.
- 58↑
Tomasik PJ, Sztefko K, Starzyk J, Rogatko I & Szafran Z. Entero-insular axis in children with anorexia nervosa. Psychoneuroendocrinology 2005 30 364–372. (https://doi.org/10.1016/j.psyneuen.2004.10.003)
- 59↑
Wojcik MH, Meenaghan E, Lawson EA, Misra M, Klibanski A & Miller KK. Reduced amylin levels are associated with low bone mineral density in women with anorexia nervosa. Bone 2010 46 796–800. (https://doi.org/10.1016/j.bone.2009.11.014)
- 60↑
Gentile MG. Enteral nutrition for feeding severely underfed patients with anorexia nervosa. Nutrients 2012 4 1293–1303. (https://doi.org/10.3390/nu4091293)
- 61↑
Redgrave GW, Coughlin JW, Schreyer CC, Martin LM, Leonpacher AK, Seide M, Verdi AM, Pletch A & Guarda AS. Refeeding and weight restoration outcomes in anorexia nervosa: challenging current guidelines. International Journal of Eating Disorders 2015 48 866–873. (https://doi.org/10.1002/eat.22390)
- 62↑
Lanfranco F, Gianotti L, Picu A, Fassino S, Abbate Daga G, Mondelli V, Giordano R, Grottoli S, Ghigo E & Arvat E. The adrenal sensitivity to ACTH stimulation is preserved in anorexia nervosa. Journal of Endocrinological Investigation 2004 27 436–441. (https://doi.org/10.1007/BF03345287)
- 63↑
Walsh BT, Roose SP, Katz JL, Dyrenfurth I, Wright L, Vande Wiele R & Glassman AH. Hypothalamic-pituitary-adrenal-cortical activity in anorexia nervosa and bulimia. Psychoneuroendocrinology 1987 12 131–140. (https://doi.org/10.1016/0306-4530(87)90043-6)
- 64↑
Hotta M, Shibasaki T, Masuda A, Imaki T, Demura H, Ling N & Shizume K. The responses of plasma adrenocorticotropin and cortisol to corticotropin-releasing hormone (CRH) and cerebrospinal fluid immunoreactive CRH in anorexia nervosa patients. Journal of Clinical Endocrinology and Metabolism 1986 62 319–324. (https://doi.org/10.1210/jcem-62-2-319)
- 65↑
Gold PW, Gwirtsman H, Avgerinos PC, Nieman LK, Gallucci WT, Kaye W, Jimerson D, Ebert M, Rittmaster R & Loriaux DL. Abnormal hypothalamic-pituitary-adrenal function in anorexia nervosa. Pathophysiologic mechanisms in underweight and weight-corrected patients. New England Journal of Medicine 1986 314 1335–1342. (https://doi.org/10.1056/NEJM198605223142102)
- 66↑
Gwirtsman HE, Kaye WH, George DT, Jimerson DC, Ebert MH & Gold PW. Central and peripheral ACTH and cortisol levels in anorexia nervosa and bulimia. Archives of General Psychiatry 1989 46 61–69. (https://doi.org/10.1001/archpsyc.1989.01810010063009)
- 67↑
Tuulari JJ, Tuominen L, de Boer FE, Hirvonen J, Helin S, Nuutila P, Nummenmaa L. Feeding releases endogenous opioids in humans. Journal of Neuroscience 2017 37 8284–8291. (https://doi.org/10.1523/JNEUROSCI.0976-17.2017)
- 68↑
Tendzegolskis Z, Viru A & Orlova E. Exercise-induced changes of endorphin contents in hypothalamus, hypophysis, adrenals and blood plasma. International Journal of Sports Medicine 1991 12 495–497. (https://doi.org/10.1055/s-2007-1024721)
- 69↑
Krahn DD, Gosnell BA, Levine AS & Morley JE. Behavioral effects of corticotropin-releasing factor: localization and characterization of central effects. Brain Research 1988 443 63–69. (https://doi.org/10.1016/0006-8993(88)91598-3)
- 70↑
Heinrichs SC, Menzaghi F, Pich EM, Baldwin HA, Rassnick S, Britton KT & Koob GF. Anti-stress action of a corticotropin-releasing factor antagonist on behavioral reactivity to stressors of varying type and intensity. Neuropsychopharmacology 1994 11 179–186. (https://doi.org/10.1038/sj.npp.1380104)
- 71↑
Shibasaki T, Kim YS, Yamauchi N, Masuda A, Imaki T, Hotta M, Demura H, Wakabayashi I, Ling N & Shizume K. Antagonistic effect of somatostatin on corticotropin-releasing factor-induced anorexia in the rat. Life Sciences 1988 42 329–334. (https://doi.org/10.1016/0024-3205(88)90642-X)
- 72↑
Stoving RK, Andersen M, Flyvbjerg A, Frystyk J, Hangaard J, Vinten J, Koldkjaer OG & Hagen C. Indirect evidence for decreased hypothalamic somatostatinergic tone in anorexia nervosa. Clinical Endocrinology 2002 56 391–396. (https://doi.org/10.1046/j.1365-2265.2002.01485.x)
- 73↑
Herpertz-Dahlmann B & Remschmidt H. [The prognostic value of the dexamethasone suppression test for the course of anorexia nervosa – comparison with depressive diseases]. Zeitschrift fur Kinder- und Jugendpsychiatrie 1990 18 5–11.
- 74↑
Andela CD, van Haalen FM, Ragnarsson O, Papakokkinou E, Johannsson G, Santos A, Webb SM, Biermasz NR, van der Wee NJA & Pereira AM. MECHANISMS IN ENDOCRINOLOGY: cushing’s syndrome causes irreversible effects on the human brain: a systematic review of structural and functional magnetic resonance imaging studies. European Journal of Endocrinology 2015 173 R1–R14. (https://doi.org/10.1530/EJE-14-1101)
- 75↑
Lebedeva A, Sundstrom A, Lindgren L, Stomby A, Aarsland D, Westman E, Winblad B, Olsson T & Nyberg L. Longitudinal relationships among depressive symptoms, cortisol, and brain atrophy in the neocortex and the hippocampus. Acta Psychiatrica Scandinavica 2018 137 491–502. (https://doi.org/10.1111/acps.12860)
- 76↑
Chan SWY, Harmer CJ, Norbury R, O’Sullivan U, Goodwin GM & Portella MJ. Hippocampal volume in vulnerability and resilience to depression. Journal of Affective Disorders 2016 189 199–202. (https://doi.org/10.1016/j.jad.2015.09.021)
- 77↑
Martin Monzon B, Henderson LA, Madden S, Macefield VG, Touyz S, Kohn MR, Clarke S, Foroughi N & Hay P. Grey matter volume in adolescents with anorexia nervosa and associated eating disorder symptoms. European Journal of Neuroscience 2017 46 2297–2307. (https://doi.org/10.1111/ejn.13659)
- 78↑
Reddy DS. Neurosteroids: endogenous role in the human brain and therapeutic potentials. Progress in Brain Research 2010 186 113–137.
- 79↑
Stein D, Maayan R, Ram A, Loewenthal R, Achiron A, Modan-Moses D, Feigin M, Weizman A & Valevski A. Circulatory neurosteroid levels in underweight female adolescent anorexia nervosa inpatients and following weight restoration. European Neuropsychopharmacology 2005 15 647–653. (https://doi.org/10.1016/j.euroneuro.2005.05.001)
- 80↑
Misra M, Miller KK, Almazan C, Ramaswamy K, Lapcharoensap W, Worley M, Neubauer G, Herzog DB & Klibanski A. Alterations in cortisol secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism. Journal of Clinical Endocrinology and Metabolism 2004 89 4972–4980. (https://doi.org/10.1210/jc.2004-0723)
- 81↑
Bou Khalil R, Souaiby L & Fares N. The importance of the hypothalamo-pituitary-adrenal axis as a therapeutic target in anorexia nervosa. Physiology and Behavior 2017 171 13–20.
- 82↑
Murphy BE. Antiglucocorticoid therapies in major depression: a review. Psychoneuroendocrinology 1997 22 (Supplement 1) S125–S132. (https://doi.org/10.1016/S0306-4530(97)00021-8)
- 83↑
Thomson F & Craighead M. Innovative approaches for the treatment of depression: targeting the HPA axis. Neurochemical Research 2008 33 691–707. (https://doi.org/10.1007/s11064-007-9518-3)
- 84↑
Paslakis G, Lecei O, Stalla GK, Landgraf R, Uhr M, Hamann B, Luppa P, Gilles M, Heuser I & Deuschle M. The effect of treatment with ketoconazole on central CRH systems of depressed patients. Human Psychopharmacology 2011 26 35–40. (https://doi.org/10.1002/hup.1167)
- 85↑
Lawson EA, Donoho D, Miller KK, Misra M, Meenaghan E, Lydecker J, Wexler T, Herzog DB & Klibanski A. Hypercortisolemia is associated with severity of bone loss and depression in hypothalamic amenorrhea and anorexia nervosa. Journal of Clinical Endocrinology and Metabolism 2009 94 4710–4716. (https://doi.org/10.1210/jc.2009-1046)
- 86↑
Chen MJ & Creinin MD. Mifepristone with buccal misoprostol for medical abortion: a systematic review. Obstetrics and Gynecology 2015 126 12–21. (https://doi.org/10.1097/AOG.0000000000000897)
- 87↑
Basina M, Liu H, Hoffman AR & Feldman D. Successful long-term treatment of Cushing disease with mifepristone (RU486). Endocrine Practice 2012 18 e114–e120. (https://doi.org/10.4158/EP11391.CR)
- 88↑
Kling MA, Demitrack MA, Whitfield HJ Jr, Kalogeras KT, Listwak SJ, DeBellis MD, Chrousos GP, Gold PW & Brandt HA. Effects of the glucocorticoid antagonist RU 486 on pituitary-adrenal function in patients with anorexia nervosa and healthy volunteers: enhancement of plasma ACTH and cortisol secretion in underweight patients. Neuroendocrinology 1993 57 1082–1091. (https://doi.org/10.1159/000126474)
- 89↑
Muller MJ, Enderle J & Bosy-Westphal A. Changes in energy expenditure with weight gain and weight loss in humans. Current Obesity Reports 2016 5 413–423. (https://doi.org/10.1007/s13679-016-0237-4)
- 90↑
Silva JE. Thyroid hormone control of thermogenesis and energy balance. Thyroid 1995 5 481–492. (https://doi.org/10.1089/thy.1995.5.481)
- 91↑
Onur S, Haas V, Bosy-Westphal A, Hauer M, Paul T, Nutzinger D, Klein H & Muller MJ. L-tri-iodothyronine is a major determinant of resting energy expenditure in underweight patients with anorexia nervosa and during weight gain. European Journal of Endocrinology 2005 152 179–184. (https://doi.org/10.1530/eje.1.01850)
- 92↑
Croxson MS & Ibbertson HK. Low serum triiodothyronine (T3) and hypothyroidism in anorexia nervosa. Journal of Clinical Endocrinology and Metabolism 1977 44 167–174. (https://doi.org/10.1210/jcem-44-1-167)
- 93↑
Tamai H, Mori K, Matsubayashi S, Kiyohara K, Nakagawa T, Okimura MC, Walter RM Jr, Kumagai LF & Nagataki S. Hypothalamic-pituitary-thyroidal dysfunctions in anorexia nervosa. Psychotherapy and Psychosomatics 1986 46 127–131. (https://doi.org/10.1159/000287973)
- 94↑
Aschettino-Manevitz DL, Ornstein RM, Meyer Sterling W, Kohn N, Fisher M. Triiodothyronine (T3) and metabolic rate in adolescents with eating disorders: is there a correlation? Eating and Weight Disorders 2012 17 e252–e258.
- 95↑
Matsubayashi S, Tamai H, Uehata S, Kobayashi N, Mori K, Nakagawa T & Kumagai LF. Anorexia nervosa with elevated serum TSH. Psychosomatic Medicine 1988 50 600–606. (https://doi.org/10.1097/00006842-198811000-00006)
- 96↑
Schebendach JE, Golden NH, Jacobson MS, Hertz S & Shenker IR. The metabolic responses to starvation and refeeding in adolescents with anorexia nervosa. Annals of the New York Academy of Sciences 1997 817 110–119. (https://doi.org/10.1111/j.1749-6632.1997.tb48200.x)
- 97↑
Stoving RK, Bennedbaek FN, Hegedus L & Hagen C. Evidence of diffuse atrophy of the thyroid gland in patients with anorexia nervosa. International Journal of Eating Disorders 2001 29 230–235. (https://doi.org/10.1002/1098-108X(200103)29:2<230::AID-EAT1013>3.0.CO;2-P)
- 98↑
Thornton LM, Welch E, Munn-Chernoff MA, Lichtenstein P & Bulik CM. Anorexia nervosa, major depression, and suicide attempts: shared genetic factors. Suicide and Life-Threatening Behavior 2016 46 525–534.
- 99↑
Samuels MH. Psychiatric and cognitive manifestations of hypothyroidism. Current Opinion in Endocrinology, Diabetes, and Obesity 2014 21 377–383. (https://doi.org/10.1097/MED.0000000000000089)
- 100↑
Kalra S & Balhara YPS. Euthyroid depression: the role of thyroid hormone. Recent Patents on Endocrine, Metabolic and Immune Drug Discovery 2014 8 38–41.
- 101↑
Thase ME, Howland RH & Friedman ES. Treating antidepressant nonresponders with augmentation strategies: an overview. Journal of Clinical Psychiatry 1998 59 (Supplement 5) 5–12; discussion 13–15.
- 103↑
van Binsbergen CJ, Coelingh Bennink HJ, Odink J, Haspels AA & Koppeschaar HP. A comparative and longitudinal study on endocrine changes related to ovarian function in patients with anorexia nervosa. Journal of Clinical Endocrinology and Metabolism 1990 71 705–711. (https://doi.org/10.1210/jcem-71-3-705)
- 104↑
Fichter MM & Pirke KM. Effect of experimental and pathological weight loss upon the hypothalamo-pituitary-adrenal axis. Psychoneuroendocrinology 1986 11 295–305. (https://doi.org/10.1016/0306-4530(86)90015-6)
- 105↑
Ordog T, Goldsmith JR, Chen MD, Connaughton MA, Hotchkiss J & Knobil E. On the mechanism of the positive feedback action of estradiol on luteinizing hormone secretion in the rhesus monkey. Journal of Clinical Endocrinology and Metabolism 1998 83 4047–4053.
- 106↑
Odle AK, Akhter N, Syed MM, Allensworth-James ML, Benes H, Melgar Castillo AI, MacNicol MC, MacNicol AM & Childs GV. Leptin regulation of gonadotrope gonadotropin-releasing hormone receptors as a metabolic checkpoint and gateway to reproductive competence. Frontiers in Endocrinology 2017 8 367. (https://doi.org/10.3389/fendo.2017.00367)
- 107↑
Misra M, Prabhakaran R, Miller KK, Tsai P, Lin A, Lee N, Herzog DB & Klibanski A. Role of cortisol in menstrual recovery in adolescent girls with anorexia nervosa. Pediatric Research 2006 59 598–603. (https://doi.org/10.1203/01.pdr.0000203097.64918.63)
- 108↑
Dei M, Seravalli V, Bruni V, Balzi D & Pasqua A. Predictors of recovery of ovarian function after weight gain in subjects with amenorrhea related to restrictive eating disorders. Gynecological Endocrinology 2008 24 459–464. (https://doi.org/10.1080/09513590802246141)
- 109↑
Krishnan S, Tryon RR, Horn WF, Welch L & Keim NL. Estradiol, SHBG and leptin interplay with food craving and intake across the menstrual cycle. Physiology and Behavior 2016 165 304–312.
- 111↑
Asarian L & Geary N. Sex differences in the physiology of eating. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology 2013 305 R1215–R1267.
- 112↑
Iwasa T, Matsuzaki T, Yano K, Mayila Y & Irahara M. The roles of kisspeptin and gonadotropin inhibitory hormone in stress-induced reproductive disorders. Endocrine Journal 2018 65 133–140. (https://doi.org/10.1507/endocrj.EJ18-0026)
- 113↑
Jacoangeli F, Masala S, Staar Mezzasalma F, Fiori R, Martinetti A, Ficoneri C, Novi B, Pierangeli S, Marchetti G & Simonetti G et al.Amenorrhea after weight recover in anorexia nervosa: role of body composition and endocrine abnormalities. Eating and Weight Disorders 2006 11 e20–e26. (https://doi.org/10.1007/BF03327748)
- 114↑
El Ghoch M, Calugi S, Chignola E, Bazzani PV & Dalle Grave R. Body fat and menstrual resumption in adult females with anorexia nervosa: a 1-year longitudinal study. Journal of Human Nutrition and Dietetics 2016 29 662–666. (https://doi.org/10.1111/jhn.12373)
- 115↑
Welt CK, Chan JL, Bullen J, Murphy R, Smith P, DePaoli AM, Karalis A & Mantzoros CS. Recombinant human leptin in women with hypothalamic amenorrhea. New England Journal of Medicine 2004 351 987–997. (https://doi.org/10.1056/NEJMoa040388)
- 116↑
Misra M, Miller KK, Almazan C, Ramaswamy K, Aggarwal A, Herzog DB, Neubauer G, Breu J & Klibanski A. Hormonal and body composition predictors of soluble leptin receptor, leptin, and free leptin index in adolescent girls with anorexia nervosa and controls and relation to insulin sensitivity. Journal of Clinical Endocrinology and Metabolism 2004 89 3486–3495. (https://doi.org/10.1210/jc.2003-032251)
- 117↑
Misra M, Golden NH & Katzman DK. State of the art systematic review of bone disease in anorexia nervosa. International Journal of Eating Disorders 2016 49 276–292. (https://doi.org/10.1002/eat.22451)
- 118↑
Sonnet E, Lacut K, Roudaut N, Mottier D, Kerlan V & Oger E. Effects of the route of oestrogen administration on IGF-1 and IGFBP-3 in healthy postmenopausal women: results from a randomized placebo-controlled study. Clinical Endocrinology 2007 66 626–631. (https://doi.org/10.1111/j.1365-2265.2007.02783.x)
- 119↑
Misra M, Katzman D, Miller KK, Mendes N, Snelgrove D, Russell M, Goldstein MA, Ebrahimi S, Clauss L & Weigel T et al.Physiologic estrogen replacement increases bone density in adolescent girls with anorexia nervosa. Journal of Bone and Mineral Research 2011 26 2430–2438. (https://doi.org/10.1002/jbmr.447)
- 120↑
Miller KK, Wexler TL, Zha AM, Lawson EA, Meenaghan EM, Misra M, Binstock AB, Herzog DB & Klibanski A. Androgen deficiency: association with increased anxiety and depression symptom severity in anorexia nervosa. Journal of Clinical Psychiatry 2007 68 959–965. (https://doi.org/10.4088/JCP.v68n0621)
- 121↑
Misra M, Katzman DK, Estella NM, Eddy KT, Weigel T, Goldstein MA, Miller KK & Klibanski A. Impact of physiologic estrogen replacement on anxiety symptoms, body shape perception, and eating attitudes in adolescent girls with anorexia nervosa: data from a randomized controlled trial. Journal of Clinical Psychiatry 2013 74 e765–e771. (https://doi.org/10.4088/JCP.13m08365)
- 122↑
Easter A, Treasure J & Micali N. Fertility and prenatal attitudes towards pregnancy in women with eating disorders: results from the Avon Longitudinal Study of Parents and Children. BJOG: An International Journal of Obstetrics and Gynaecology 2011 118 1491–1498. (https://doi.org/10.1111/j.1471-0528.2011.03077.x)
- 123↑
Madsen IR, Horder K & Stoving RK. Remission of eating disorder during pregnancy: five cases and brief clinical review. Journal of Psychosomatic Obstetrics and Gynaecology 2009 30 122–126. (https://doi.org/10.1080/01674820902789217)
- 124↑
Kimmel MC, Ferguson EH, Zerwas S, Bulik CM & Meltzer-Brody S. Obstetric and gynecologic problems associated with eating disorders. International Journal of Eating Disorders 2016 49 260–275. (https://doi.org/10.1002/eat.22483)
- 125↑
Stoving RK, Veldhuis JD, Flyvbjerg A, Vinten J, Hangaard J, Koldkjaer OG, Kristiansen J & Hagen C. Jointly amplified basal and pulsatile growth hormone (GH) secretion and increased process irregularity in women with anorexia nervosa: indirect evidence for disruption of feedback regulation within the GH-insulin-like growth factor I axis. Journal of Clinical Endocrinology and Metabolism 1999 84 2056–2063.
- 126↑
Misra M, Miller KK, Bjornson J, Hackman A, Aggarwal A, Chung J, Ott M, Herzog DB, Johnson ML & Klibanski A. Alterations in growth hormone secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism. Journal of Clinical Endocrinology and Metabolism 2003 88 5615–5623. (https://doi.org/10.1210/jc.2003-030532)
- 127↑
Morselli LL, Nedeltcheva A, Leproult R, Spiegel K, Martino E, Legros JJ, Weiss RE, Mockel J, Van Cauter E & Copinschi G. Impact of GH replacement therapy on sleep in adult patients with GH deficiency of pituitary origin. European Journal of Endocrinology 2013 168 763–770. (https://doi.org/10.1530/EJE-12-1037)
- 128↑
Stoving RK, Flyvbjerg A, Frystyk J, Fisker S, Hangaard J, Hansen-Nord M & Hagen C. Low serum levels of free and total insulin-like growth factor I (IGF-I) in patients with anorexia nervosa are not associated with increased IGF-binding protein-3 proteolysis. Journal of Clinical Endocrinology and Metabolism 1999 84 1346–1350.
- 129↑
Fazeli PK & Klibanski A. Determinants of GH resistance in malnutrition. Journal of Endocrinology 2014 220 R57–R65. (https://doi.org/10.1530/JOE-13-0477)
- 130↑
Xie T & Leung PS. Fibroblast growth factor 21: a regulator of metabolic disease and health span. American Journal of Physiology, Endocrinology and Metabolism 2017 313 E292–E302. (https://doi.org/10.1152/ajpendo.00101.2017)
- 131↑
Fazeli PK, Misra M, Goldstein M, Miller KK & Klibanski A. Fibroblast growth factor-21 may mediate growth hormone resistance in anorexia nervosa. Journal of Clinical Endocrinology and Metabolism 2010 95 369–374. (https://doi.org/10.1210/jc.2009-1730)
- 133↑
Leger J, Fjellestad-Paulsen A, Bargiacchi A, Doyen C, Ecosse E, Carel J-C & Le Heuzey M-F. Can growth hormone treatment improve growth in children with severe growth failure due to anorexia nervosa? A preliminary pilot study. Endocrine Connections 2017 6 839–846. (https://doi.org/10.1530/EC-17-0200)
- 134↑
Haruta I, Fuku Y, Kinoshita K, Yoneda K, Morinaga A, Amitani M, Amitani H, Asakawa A, Sugawara H & Takeda Y et al.One-year intranasal application of growth hormone releasing peptide-2 improves body weight and hypoglycemia in a severely emaciated anorexia nervosa patient. Journal of Cachexia, Sarcopenia and Muscle 2015 6 237–241. (https://doi.org/10.1002/jcsm.12028)
- 135↑
Fazeli PK, Lawson EA, Prabhakaran R, Miller KK, Donoho DA, Clemmons DR, Herzog DB, Misra M & Klibanski A. Effects of recombinant human growth hormone in anorexia nervosa: a randomized, placebo-controlled study. Journal of Clinical Endocrinology and Metabolism 2010 95 4889–4897. (https://doi.org/10.1210/jc.2010-0493)
- 136↑
Takala J, Ruokonen E, Webster NR, Nielsen MS, Zandstra DF, Vundelinckx G & Hinds CJ. Increased mortality associated with growth hormone treatment in critically ill adults. New England Journal of Medicine 1999 341 785–792. (https://doi.org/10.1056/NEJM199909093411102)
- 137↑
Luquet S, Perez FA, Hnasko TS & Palmiter RD. NPY/AgRP neurons are essential for feeding in adult mice but can be ablated in neonates. Science 2005 310 683–685. (https://doi.org/10.1126/science.1115524)
- 138↑
Ibrahim Abdalla MM. Ghrelin – physiological functions and regulation. European Endocrinology 2015 11 90–95. (https://doi.org/10.17925/EE.2015.11.02.90)
- 139↑
Zhao T-J, Liang G, Li RL, Xie X, Sleeman MW, Murphy AJ, Valenzuela DM, Yancopoulos GD, Goldstein JL, Brown MS. Ghrelin O-acyltransferase (GOAT) is essential for growth hormone-mediated survival of calorie-restricted mice. PNAS 2010 107 7467–7472. (https://doi.org/10.1073/pnas.1002271107)
- 140↑
Gnanapavan S, Kola B, Bustin SA, Morris DG, McGee P, Fairclough P, Bhattacharya S, Carpenter R, Grossman AB & Korbonits M. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. Journal of Clinical Endocrinology and Metabolism 2002 87 2988. (https://doi.org/10.1210/jcem.87.6.8739)
- 141↑
Howick K, Griffin BT, Cryan JF & Schellekens H. From belly to brain: targeting the ghrelin receptor in appetite and food intake regulation. International Journal of Molecular Sciences 2017 18.
- 142↑
Collden G, Tschop MH & Muller TD. Therapeutic potential of targeting the ghrelin pathway. International Journal of Molecular Sciences 2017 18 798. (https://doi.org/10.3390/ijms18040798)
- 143↑
Gorwood P, Blanchet-Collet C, Chartrel N, Duclos J, Dechelotte P, Hanachi M, Fetissov S, Godart N, Melchior JC & Ramoz N et al.New insights in anorexia nervosa. Frontiers in Neuroscience 2016 10 256.
- 144↑
Misra M, Miller KK, Tsai P, Gallagher K, Lin A, Lee N, Herzog DB & Klibanski A. Elevated peptide YY levels in adolescent girls with anorexia nervosa. Journal of Clinical Endocrinology and Metabolism 2006 91 1027–1033. (https://doi.org/10.1210/jc.2005-1878)
- 145↑
Otto B, Cuntz U, Fruehauf E, Wawarta R, Folwaczny C, Riepl RL, Heiman ML, Lehnert P, Fichter M & Tschop M. Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. European Journal of Endocrinology 2001 145 669–673. (https://doi.org/10.1530/eje.0.1450669)
- 146↑
Soriano-Guillen L, Barrios V, Campos-Barros A & Argente J. Ghrelin levels in obesity and anorexia nervosa: effect of weight reduction or recuperation. Journal of Pediatrics 2004 144 36–42. (https://doi.org/10.1016/j.jpeds.2003.10.036)
- 147↑
Misra M, Miller KK, Kuo K, Griffin K, Stewart V, Hunter E, Herzog DB & Klibanski A. Secretory dynamics of ghrelin in adolescent girls with anorexia nervosa and healthy adolescents. American Journal of Physiology: Endocrinology and Metabolism 2005 289 E347–E356.
- 148↑
Janas-Kozik M, Krupka-Matuszczyk I, Malinowska-Kolodziej I & Lewin-Kowalik J. Total ghrelin plasma level in patients with the restrictive type of anorexia nervosa. Regulatory Peptides 2007 140 43–46. (https://doi.org/10.1016/j.regpep.2006.11.005)
- 149↑
Monteleone P, Serritella C, Martiadis V, Scognamiglio P & Maj M. Plasma obestatin, ghrelin, and ghrelin/obestatin ratio are increased in underweight patients with anorexia nervosa but not in symptomatic patients with bulimia nervosa. Journal of Clinical Endocrinology and Metabolism 2008 93 4418–4421. (https://doi.org/10.1210/jc.2008-1138)
- 150↑
Tanaka M, Naruo T, Yasuhara D, Tatebe Y, Nagai N, Shiiya T, Nakazato M, Matsukura S, Nozoe S-i. Fasting plasma ghrelin levels in subtypes of anorexia nervosa. Psychoneuroendocrinology 2003 28 829–835. (https://doi.org/10.1016/S0306-4530(02)00066-5)
- 151↑
Monteleone P, Tortorella A, Castaldo E, Di Filippo C & Maj M. No association of the Arg51Gln and Leu72Met polymorphisms of the ghrelin gene with anorexia nervosa or bulimia nervosa. Neuroscience Letters 2006 398 325–327. (https://doi.org/10.1016/j.neulet.2006.01.023)
- 153↑
Hotta M, Ohwada R, Akamizu T, Shibasaki T, Takano K & Kangawa K. Ghrelin increases hunger and food intake in patients with restricting-type anorexia nervosa: a pilot study. Endocrine Journal 2009 56 1119–1128. (https://doi.org/10.1507/endocrj.K09E-168)
- 154↑
Kawai K, Nakashima M, Kojima M, Yamashita S, Takakura S, Shimizu M, Kubo C & Sudo N. Ghrelin activation and neuropeptide Y elevation in response to medium chain triglyceride administration in anorexia nervosa patients. Clinical Nutrition 2017 17 100–104.
- 155↑
Neary NM, Small CJ, Wren AM, Lee JL, Druce MR, Palmieri C, Frost GS, Ghatei MA, Coombes RC & Bloom SR. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism 2004 89 2832–2836. (https://doi.org/10.1210/jc.2003-031768)
- 156↑
Nagaya N, Itoh T, Murakami S, Oya H, Uematsu M, Miyatake K & Kangawa K. Treatment of cachexia with ghrelin in patients with COPD. Chest 2005 128 1187–1193. (https://doi.org/10.1378/chest.128.3.1187)
- 157↑
Strasser F, Lutz TA, Maeder MT, Thuerlimann B, Bueche D, Tschop M, Kaufmann K, Holst B, Brandle M & von Moos R et al.Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer 2008 98 300–308. (https://doi.org/10.1038/sj.bjc.6604148)
- 158↑
Weterle-Smolinska KA, Banasiuk M, Dziekiewicz M, Ciaston M, Jagielska G & Banaszkiewicz A. Gastrointestinal motility disorders in patients with anorexia nervosa – a review of the literature. Psychiatria Polska 2015 49 721–729. (https://doi.org/10.12740/PP/35482)
- 159↑
Wo JM, Ejskjaer N, Hellstrom PM, Malik RA, Pezzullo JC, Shaughnessy L, Charlton P, Kosutic G & McCallum RW. Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting – randomised clinical study subset data. Alimentary Pharmacology and Therapeutics 2011 33 679–688.
- 160↑
Fazeli PK, Lawson EA, Faje AT, Eddy KT, Lee H, Fiedorek FT, Breggia A, Gaal IM, DeSanti R & Klibanski A. Treatment with a ghrelin agonist in outpatient women with anorexia nervosa: a randomized clinical trial. Journal of Clinical Psychiatry 2018 79 17m11585 e1–17m11585 e7.
- 161↑
Foltin RW, Brady JV & Fischman MW. Behavioral analysis of marijuana effects on food intake in humans. Pharmacology, Biochemistry, and Behavior 1986 25 577–582. (https://doi.org/10.1016/0091-3057(86)90144-9)
- 162↑
Hollister LE. Hunger and appetite after single doses of marihuana, alcohol, and dextroamphetamine. Clinical Pharmacology and Therapeutics 1971 12 44–49. (https://doi.org/10.1002/cpt197112144)
- 163↑
Nelson K, Walsh D, Deeter P & Sheehan F. A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. Journal of Palliative Care 1994 10 14–18.
- 164↑
Beal JE, Olson R, Laubenstein L, Morales JO, Bellman P, Yangco B, Lefkowitz L, Plasse TF & Shepard KV. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. Journal of Pain and Symptom Management 1995 10 89–97. (https://doi.org/10.1016/0885-3924(94)00117-4)
- 165↑
Ceccarini J, Weltens N, Ly HG, Tack J, Van Oudenhove L & Van Laere K. Association between cerebral cannabinoid 1 receptor availability and body mass index in patients with food intake disorders and healthy subjects: a [(18)F]MK-9470 PET study. Translational Psychiatry 2016 6 e853. (https://doi.org/10.1038/tp.2016.118)
- 166↑
Monteleone AM, Di Marzo V, Aveta T, Piscitelli F, Dalle Grave R, Scognamiglio P, El Ghoch M, Calugi S, Monteleone P & Maj M. Deranged endocannabinoid responses to hedonic eating in underweight and recently weight-restored patients with anorexia nervosa. American Journal of Clinical Nutrition 2015 101 262–269. (https://doi.org/10.3945/ajcn.114.096164)
- 167↑
Davis C & Woodside DB. Sensitivity to the rewarding effects of food and exercise in the eating disorders. Comprehensive Psychiatry 2002 43 189–194. (https://doi.org/10.1053/comp.2002.32356)
- 168↑
Monteleone P, Matias I, Martiadis V, De Petrocellis L, Maj M & Di Marzo V. Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology 2005 30 1216–1221. (https://doi.org/10.1038/sj.npp.1300695)
- 169↑
Andries A & Stoving RK. Cannabinoid-1 receptor agonists: a therapeutic option in severe, chronic anorexia nervosa?